BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33262524)

  • 1. miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.
    Vu TT; Stölzel F; Wang KW; Röllig C; Tursky ML; Molloy TJ; Ma DD
    Leukemia; 2021 Jul; 35(7):1933-1948. PubMed ID: 33262524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
    Ishizawa J; Nakamaru K; Seki T; Tazaki K; Kojima K; Chachad D; Zhao R; Heese L; Ma W; Ma MCJ; DiNardo C; Pierce S; Patel KP; Tse A; Davis RE; Rao A; Andreeff M
    Cancer Res; 2018 May; 78(10):2721-2731. PubMed ID: 29490944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
    Kojima K; Konopleva M; Samudio IJ; Shikami M; Cabreira-Hansen M; McQueen T; Ruvolo V; Tsao T; Zeng Z; Vassilev LT; Andreeff M
    Blood; 2005 Nov; 106(9):3150-9. PubMed ID: 16014563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.
    Carter BZ; Mak DH; Schober WD; Koller E; Pinilla C; Vassilev LT; Reed JC; Andreeff M
    Blood; 2010 Jan; 115(2):306-14. PubMed ID: 19897582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
    Kojima K; Konopleva M; Tsao T; Nakakuma H; Andreeff M
    Blood; 2008 Oct; 112(7):2886-95. PubMed ID: 18633130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
    McCormack E; Haaland I; Venås G; Forthun RB; Huseby S; Gausdal G; Knappskog S; Micklem DR; Lorens JB; Bruserud O; Gjertsen BT
    Leukemia; 2012 May; 26(5):910-7. PubMed ID: 22064349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.
    Zhang H; Kang J; Liu L; Chen L; Ren S; Tao Y
    Aging (Albany NY); 2020 Oct; 12(20):20111-20126. PubMed ID: 33077697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
    Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
    Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia.
    Tan BX; Khoo KH; Lim TM; Lane DP
    Oncotarget; 2014 Feb; 5(4):933-43. PubMed ID: 24659749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Casein kinase 1α inhibits p53 downstream of MDM2‑mediated autophagy and apoptosis in acute myeloid leukemia.
    Xu W; Huang Z; Gan Y; Chen R; Huang Y; Xue B; Jiang S; Yu Z; Yu K; Zhang S
    Oncol Rep; 2020 Nov; 44(5):1895-1904. PubMed ID: 32901886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
    Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
    Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
    Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.
    Pardee TS
    PLoS One; 2012; 7(8):e43185. PubMed ID: 22905229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
    Kojima K; Konopleva M; Samudio IJ; Ruvolo V; Andreeff M
    Cancer Res; 2007 Apr; 67(7):3210-9. PubMed ID: 17409429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
    Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
    Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
    Thompson T; Andreeff M; Studzinski GP; Vassilev LT
    Mol Cancer Ther; 2010 May; 9(5):1158-68. PubMed ID: 20406950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation.
    Borthakur G; Duvvuri S; Ruvolo V; Tripathi DN; Piya S; Burks J; Jacamo R; Kojima K; Ruvolo P; Fueyo-Margareto J; Konopleva M; Andreeff M
    PLoS One; 2015; 10(10):e0139254. PubMed ID: 26440941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.
    Duan L; Perez RE; Lai X; Chen L; Maki CG
    J Biol Chem; 2019 Jun; 294(23):9186-9197. PubMed ID: 31036564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.